News

The study, named DIAS2, will be a multinational, randomized, parallel-design dose-ranging study to confirm the results of earlier phase II studies. These studies demonstrated the potential of desmoteplase

The collaboration will focus on developing novel drug-device combinations incorporating RNAi therapeutics. RNAi, or RNA interference, refers to a technique for silencing targeted genes in a cell, inhibiting

Based on successful results of this pilot pharmacokinetic trial in healthy volunteers, Hana intends to file an investigational new drug (IND) application to commence an abbreviated clinical development

West received $7.1 million cash, approximately 14% of the stock of Archimedes Pharma, and a royalty interest in certain of Archimedes Pharma’s revenues in exchange for substantially all

ParinGenix is developing PGX-100 to ameliorate cardiac ischemia-reperfusion injury following myocardial infarction (heart attack), including both ST-elevated and non-Q-wave myocardial infarctions. Evaluation of PGX-100 in animal models shows

Sinovac paid cash for the 20.56% of Sinovac (Beijing), to China Bioway Biotech Group Co Ltd, Shenzhen Bio-Port Co Ltd and Beijing Keding Co Ltd. Sinovac’s holdings now

Under the terms of the new agreement, Albany Molecular Research will provide fee-for-service chemistry research on projects in strategic therapeutic areas identified by Eli Lilly. Specific financial details

In partnership with Cyclone Commerce, GlobalNet will work to centralize the receipt of submissions from regulated industry and other government agencies into a single system. According to InformationWeek,

A Los Angeles Times article reported that Merck executives knew of the health threat posed to children, as a company memo from 1991 stated that six-month-old children receiving